The justification for pursuing these large-scale gene identification efforts, which are costly endeavors that require coordination and collaboration across hundreds of scientific groups [The Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium, 2011], is often that identifying genes influencing disorder will help advance understanding of the underlying biology (Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014), and be useful in developing new therapeutic drugs (Sanseau et al., 2012, So et al., 2017). This argument can be found in both the scientific literature (Breen et al., 2016), and in lay descriptions about the importance of genetic studies of psychiatric disorders (Yilmaz, 2016). One of the challenges with drug development for psychiatric outcomes is the limited understanding of underlying biology, and likely complex heterogeneity of etiological factors. GWAS findings can be used to identify genes, and the proteins and networks that interact with identified genes, providing potential targets for drug discovery or drug repositioning (De Jong et al., 2016). The most recent phase of the PGC proposes pathway analyses that integrate data from GWAS findings with information about potential druggable targets to
